What changed: Small-cell lung cancer
Every dated change on the records linked to Small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 6
- 2026ApprovalLurbinectedinLurbinectedin approved in EU
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
- 2026ApprovalTarlatamabTarlatamab approved in EU
ES-SCLC after platinum-based chemotherapy; 29 May 2026
- 2026GuidelineSmall-cell lung cancerGuideline NCCN SCLC v2.2026: Limited stage
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance. (NCCN 1 (durvalumab consolidation, category 1), ESMO-MCBS A)
- 2026GuidelineSmall-cell lung cancerGuideline NCCN SCLC v2.2026: Screening and diagnosis
Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI. (NCCN SCLC guideline, staging workup)
- 2026Trial resultDeLLphi-305DeLLphi-305 reported
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
- 2026MilestoneIDeate-Lung02Phase 3 readouts pending for I-DXd and tarlatamab maintenance
A milestone in how this cancer is treated.
December 2025 · 1
October 2025 · 1
June 2025 · 1
February 2025 · 1
2025 · 6
- 2025ApprovalLurbinectedinLurbinectedin approved in US
First-line maintenance with atezolizumab in ES-SCLC (full approval)
- 2025ApprovalSerplulimabSerplulimab approved in EU
First-line ES-SCLC with carboplatin-etoposide
- 2025RegulatorySerplulimabSerplulimab: approval (UK)
MHRA approval
- 2025Trial resultDeLLphi-304DeLLphi-304 reported
OS HR 0.
- 2025Trial resultIMforteIMforte reported
OS 13.
- 2025MilestoneDeLLphi-304DeLLphi-304 OS benefit and full approval of tarlatamab; IMforte maintenance approved
A milestone in how this cancer is treated.
December 2024 · 1
August 2024 · 1
May 2024 · 1
2024 · 5
- 2024ApprovalBenmelstobartBenmelstobart approved in CN
Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy
- 2024ApprovalTarlatamabTarlatamab approved in US
Extensive-stage SCLC after platinum chemotherapy
- 2024Trial resultADRIATICADRIATIC reported
OS 55.
- 2024MilestoneTarlatamabTarlatamab accelerated approval; ADRIATIC changes limited-stage care
A milestone in how this cancer is treated.
- 2024MilestoneTarlatamabTarlatamab approved
A milestone in how this cancer is treated.
2023 · 1
November 2022 · 1
2022 · 3
October 2021 · 1
2021 · 3
- 2021ApprovalTrilaciclibTrilaciclib approved in US
To decrease chemotherapy-induced myelosuppression in adults receiving platinum-etoposide or topotecan for extensive-stage small cell lung cancer
- 2021Trial resultATLANTISATLANTIS reported
OS HR 0.
- 2021MilestoneSubtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)SCLC molecular subtypes (A, N, P, I) proposed
A milestone in how this cancer is treated.
December 2020 · 1
June 2020 · 1
March 2020 · 1
2020 · 3
- 2020ApprovalLurbinectedinLurbinectedin approved in US
Metastatic SCLC after platinum chemotherapy (accelerated)
- 2020ApprovalOsimertinibOsimertinib approved in US
Adjuvant EGFR-mutant NSCLC
- 2020MilestoneLurbinectedinLurbinectedin accelerated approval in relapsed SCLC
A milestone in how this cancer is treated.
March 2019 · 1
2019 · 4
- 2019Trial resultCASPIANCASPIAN reported
OS 13.
- 2019MilestoneCASPIANCASPIAN confirms chemo-immunotherapy with durvalumab
A milestone in how this cancer is treated.
- 2019MilestoneSmall-cell lung cancerRovalpituzumab tesirine (first DLL3 ADC) fails
A milestone in how this cancer is treated.
- 2019MilestoneDLL3Rovalpituzumab tesirine (first DLL3 ADC) fails
A milestone in how this cancer is treated.
April 2018 · 1
February 2018 · 1
2018 · 6
- 2018ApprovalAnlotinibAnlotinib approved in China
Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)
- 2018ApprovalDurvalumabDurvalumab approved in US
Unresectable stage III NSCLC after chemoradiation
- 2018ApprovalOsimertinibOsimertinib approved in US
First-line EGFR-mutant NSCLC
- 2018Trial resultIMpower133IMpower133 reported
OS 12.
- 2018MilestoneAtezolizumabIMpower133: first immunotherapy OS benefit
A milestone in how this cancer is treated.
- 2018MilestoneIMpower133IMpower133: first survival gain in decades with atezolizumab
A milestone in how this cancer is treated.
2017 · 4
- 2017Trial resultCONVERTCONVERT reported
No significant difference; twice-daily 45 Gy remains standard.
- 2017Trial resultTakahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancerTakahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer reported
Median overall survival 11.
- 2017MilestoneCONVERTCONVERT: once-daily 66 Gy not superior to twice-daily 45 Gy
A milestone in how this cancer is treated.
- 2017MilestoneProphylactic cranial irradiation vs MRI surveillanceJapanese trial: PCI gives no survival benefit in extensive-stage disease with MRI surveillance
A milestone in how this cancer is treated.
October 2016 · 1
2016 · 1
November 2015 · 1
2015 · 1
2007 · 2
- 2007ApprovalTopotecanTopotecan approved in US
Relapsed SCLC (oral)
- 2007Trial resultEORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancerEORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer reported
Symptomatic brain metastases at 1 year 14.
1999 · 2
- 1999MilestoneProphylactic cranial irradiation vs MRI surveillanceProphylactic cranial irradiation improves survival in complete responders
A milestone in how this cancer is treated.
- 1999MilestoneIMRT / IGRT (modern external beam)Twice-daily 45 Gy (Turrisi) sets the limited-stage radiotherapy standard
A milestone in how this cancer is treated.